FDA requests additional data on CMC section of NDA for taliglucerase alfa from Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. (NYSE Amex: PLX) announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.  No additional Clinical or Preclinical information was requested.  The request focused primarily on validation of the manufacturing process in the Company's upgraded manufacturing facility.  A validation plan for the Company's manufacturing process of taliglucerase alfa has already been established and reviewed by the FDA.  The Company is working diligently to provide the requested data to the FDA and anticipates submitting the requested data during the second quarter of 2010.

Based on the FDA's request as part of its rolling review of the NDA, the Prescription Drug User Fee Act (PDUFA) action date for taliglucerase alfa is expected to be issued following submission of the additional requested CMC data.

Taliglucerase alfa will continue being provided to Gaucher patients in the United States under an Expanded Access protocol, as well as to patients in the European Union, Israel and other countries under Named Patient provisions.  

SOURCE Protalix BioTherapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Surfactant-coated nanoparticle applications in nanomedicine and food